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Abstract  29 
Intravenous (IV) Cefuroxime (CFX) is widely used in Caesarean Section (CS) as a prophylactic 30 
antibiotic. The objective of this systematic review to compare CFX concentration in maternal 31 
blood and adipose tissue with the incidence of surgical site infection (SSI) following IV CFX in 32 
non-obese and obese women undergoing CS. A search in Medline, EMBASE, Cochrane, Web 33 
of Science, CINHAL Plus, Scopus and Google Scholar was conducted without language or 34 
date restrictions. Published articles or abstracts reporting CFX concentration or rates of SSI 35 
following CFX IV administration in adult women requiring CS were included. Studies were 36 
screened by title and abstract. Quality of studies was assessed via the ClinPK Statement 37 
checklist (Pharmacokinetics studies), or Joanna Briggs Institute Critical Appraisal Tools (SSI 38 
studies). The Cochrane Effective Practice and Organisation of Care checklist evaluated the 39 
risk of bias (SSI studies). There were no studies evaluating CFX concentrations in obese 40 
women undergoing CS. For non-obese women, CFX plasma concentrations ranged from 9.85 41 
to 95.25mg/L within 30-60min of administration (1500mg dose; 4 articles, n=108 women). 42 
Plasma CFX concentrations were above the minimum inhibitory concentration (8mg/L) for 43 
up to 3 hours post-dose. No studies reported on CFX concentration in adipose tissue. 44 
Reported rates of SSI were 4.7% and 6.8% after administration of a single 1500mg dose of 45 
CFX administrated after cord clamping (n=144 women). There is limited data on 46 
pharmacokinetics of CFX for CS. There were no studies that reported CFX concentrations or 47 
SSI in obese women.  48 
Funding: Not applicable. 49 
Keywords: Cefuroxime; Caesarean Section; Pharmacokinetics; Surgical Site Infection; 50 
Pregnant women; obese. 51 
2 
 
Introduction 52 
The use of perioperative antibiotics has transformed the surgical landscape and it is 53 
standard practice for intravenous (IV) administration of a broad-spectrum antibiotic to 54 
minimise the incidence of surgical site infection (SSI). A single dose of IV prophylactic 55 
antibiotics is recommended at the time of caesarean section (CS) before skin incision(1). 56 
However, it is unclear if there is any advantage of one antibiotic over another, both in terms 57 
of choice of drug and dosage, in obese women undergoing CS. (1-4) 58 
The prevalence of maternal obesity varies across the UK; in the East of England, the rate is 59 
6.23%, whilst in London 3.46% are obese(5). The rate of CS  in the obese population is 33.8% 60 
rising to 47.4% in class II or III obesity(6). The rate of post-CS infection is higher among 61 
obese pregnant women compared to those who are not obese (7). Women who were 62 
overweight, obese and morbidly obese had an adjusted odds ratio for infection of 1.64 (95% 63 
CI 1.22-2.1), 2.41 (95%CI 1.73-3.37) and 3.67 (95%CI 2.62-5.16) respectively (7).  64 
The optimal doses of peri-CS antibiotics in the obese pregnant population is unclear. Several 65 
studies have investigated an increased dose of cefazolin (CFZ) (3 g) for obese pregnant 66 
women to achieve adequate antibiotic levels compared to the usual dose (2g) (8-10). 67 
Cefuroxime (CFX) is a second-generation cephalosporin, used in pregnancy due to a low 68 
incidence of side effects and a low level of protein binding (11). As with CFZ, CFX is excreted 69 
in an unaltered form by the kidneys. However, the lipophilicity of CFX is much lower than 70 
CFZ (logP values -0.167 vs. 0.3) (11-14). Therefore, higher doses of CFX may be required to 71 
achieve adequate adipose tissue levels and thus prevent SSI. The minimum inhibitory 72 
concentration (MIC) is the lowest concentration of an antibiotic that inhibits the growth of a 73 
certain strain of bacteria. The MIC of CFX for the most common causative bacteria of post-74 
3 
 
CS infections is <1mg/L (15). Certain strains may require a higher concentration of 4mg/L or 75 
8mg/L(16-18). In this review, MIC of 4 and 8 mg/L were chosen to evaluate appropriate CFX 76 
coverage for the intended population to ensure proper antibiotic coverage against these 77 
strains.  78 
We sought to systematically review the literature to compare CFX concentrations in plasma 79 
and subcutaneous adipose tissue in non-obese and obese pregnant women requiring CS 80 
who were administered IV CFX peri-operatively; and to compare incidence of SSI in both 81 
groups.  82 
Due to variations in reported data for pharmacokinetics (PK) and the infection rates, we 83 
conducted separate systematic reviews for each output parameter:  (a) the CFX PK 84 
systematic review (CFX-PK) of studies on CFX concentrations in plasma and adipose tissue in 85 
pregnant women and (b) the systematic review of CFX and postsurgical infection (CFX-INF). 86 
Scope of the Research 87 
In March 2018, a search was conducted using the Cochrane Library’s Cochrane Database of 88 
Systematic Reviews (CDSR) to identify any systematic reviews or meta-analyses addressing 89 
the search questions. There were no systematic reviews or meta-analyses evaluating the PK 90 
or rate of infection of CFX in pregnant women undergoing CS.  91 
Reporting Strategy 92 
The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 93 
checklist was used as guidance thorough this systematic review (Appendixes: Table S7) (19). 94 
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Methods  95 
Search Strategy and data bases 96 
Relevant electronic databases were searched using a research strategy that was constructed 97 
using Medical Subject Headings (MeSH) terms and keywords from MEDLINE, using the term 98 
harvesting template suggested by the National Institute of Health (Appendixes: S1). The 99 
strategy was then adapted to the other databases to establish homogenous search terms in 100 
all the databases selected (Appendixes: Table S6). 101 
The following databases were searched including all available years, with no restrictions on 102 
the language or study setting: MEDLINE/Ovid (1948 to March 2018), Embase (1974 to March 103 
2018), the Cochrane Library’s CDSR, CINAHL Plus, Scopus and Web of Science (search until 104 
March 2018 for CFX-PK, until April for CFX-INF). The search was updated in May 2019. 105 
An additional specific search was conducted using Google Scholar, with the following 106 
phrases for each systematic review with no time restrictions. The first two-hundred titles 107 
were reviewed. 108 
1- CFX-PK “pharmacokinetics of cefuroxime in pregnancy”. Last searched on 31 May 2019 109 
2- CFX-INF “Cefuroxime and infection in caesarean section”. Last searched on 31 May 2019 110 
The references of the included articles, were screened to identify additional articles of 111 
interest; the articles identified were then added and screened for eligibility.  112 
Protocol and registration 113 
The systematic reviews’ protocols were registered on the International prospective register 114 
of systematic reviews (CRD42018106945 and CRD42018107192). 115 
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Relevant Articles 116 
References yielded from the databases were exported into EndNote X8, and the duplicates 117 
were removed. The articles were then screened by titles and abstracts (Appendices Table 118 
S1). Full text of each article was examined to further assess eligibility. 119 
Quality Assessment and Risk of Bias  120 
The quality and risk of bias assessment were done by two reviewers (HA, HB), in case of 121 
conflicts, a discussion was made with a third reviewer for a final decision (HC).  122 
Pharmacokinetics studies: 123 
For the CFX-PK, the ClinPK Statement checklist was used to evaluate the quality of the 124 
methodology in each of the PK studies and risk of bias(20). This checklist was 125 
comprehensively formulated specifically for PK studies; it was used previously in a similar 126 
study (21). The checklist contained 24 items; however, 4 items (11, 12, 20 and 21) were 127 
excluded from this study because they were irrelevant to the inclusion criteria (Appendices: 128 
Table S2). If the item was applicable and existed in the study, it was scored as 2. If the item 129 
was applicable and did not exist in the study, it was scored as a 0 for that item. If the item 130 
was not applicable or there was insufficient data, the item was scored as 1. Therefore, the 131 
total score for the modified ClinPK Statement checklist used in this study was 40.  132 
Infection studies:  133 
Study quality for CFX-INF was assessed by the Joanna Briggs Institute (JBI) Critical Appraisal 134 
Tools (22). This tool was selected as it comprehensively assesses different types of study 135 
design. For the risk of bias, the Cochrane Effective Practice and Organisation of Care (EPOC) 136 
checklist was used (23). 137 
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Data Analysis 138 
Whenever applicable, the mean and standard deviation (SD) was calculated for the 139 
concentration or rate of infection. Meta-analysis and statistical analysis was performed 140 
where applicable. 141 
Results 142 
Cefuroxime pharmacokinetics systematic review  143 
Literature Retrieval and Study Selection  144 
Sixty-six titles were identified from the search strategy. After removing duplicates, 48 145 
records were screened for inclusion based on the titles and abstracts, resulting in 37 studies 146 
being excluded (Figure 1). The full text of 11 studies were reviewed to assess eligibility. Four 147 
studies fulfilled the inclusion criteria, and were evaluated for the risk of bias and quality. The 148 
PK data was then extracted for further analysis. None of those studies reported PK in obese 149 
pregnant women. No additional studies were identified that were eligible for inclusion in 150 
the updated search conducted in May 2019. 151 
Data Extraction 152 
The PK data was extracted from the studies directly as reported or calculated based on 153 
figures presented (e.g. extraction from the time-concentration curve using an online 154 
website (24)) (Table 1). A time-concentration curve was generated for each of the included 155 
studies (Figure 2). In the study by Bousfield et al.(25), the data provided for the maternal 156 
blood was presented as scattered data in a graph with no differentiation of each time-point 157 
for each patient, nor mean plasma concentration for each time point, based on 10 patients.  158 
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Comparison of PK findings from Cefuroxime dose in women prior to CS 159 
The studies identified in non-obese pregnant women will be discussed in chronological 160 
order in order to evaluate the growing body of knowledge of CFX PK in CS. It should be 161 
noted that the quality of three of the studies was low. The ClinPK Statement checklist scores 162 
were 24, 25 and 31 out of 40 for the Bousfield et al.(25), Roumen et al.(26) and Holt et 163 
al.(15) studies, respectively. However, Lalic-Popovic et al.(11) scored higher, with a ClinPK 164 
Statement checklist score of 38/40 (Appendixes: Table S3). All studies were included, 165 
despite low ClinPK score, due to the paucity of data identified. This difference in quality was 166 
primarily due to the date of publication and the greater emphasis on methodology and 167 
reporting in recent times. All of the studies measured CFX concentrations using high-168 
performance liquid chromatography, with the exception of the study by Bousfield et al.(25), 169 
in which the agar plate diffusion method was used. None of the included studies 170 
investigated CFX adipose tissue concentrations.  171 
At time points closest to one hour, there was great variation in reported mean CFX 172 
concentrations: 9.47 mg/L, 32.55 mg/L and 74.76 mg/L in Lalic-Popovic et al.(11), Roumen et 173 
al.(26) and Bousfield et al.(25) studies, respectively (average CFX concentration was 174 
calculated from four points closer to one hour in Bousfield et al.(25)). These differences may 175 
relate to the interpatient variability or the assay methods used.  176 
Bousfield et al.(25) investigated an IV bolus administration of 1500 mg of CFX pre-delivery in 177 
10 pregnant women in labour who delivered vaginally and 10 pregnant women scheduled 178 
for elective CS. In the CS deliveries, the CFX injection time varied from 48 min to 337 min 179 
prior to delivery. The maternal blood was analysed for CFX quantification before delivery 180 
and at 30 min intervals until delivery.  181 
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Roumen et al.(26) evaluated the PK of CFX in 6 pregnant patients with preterm premature 182 
membrane ruptures, 4 of whom underwent CS. The authors measured CFX concentrations 183 
in the maternal plasma, amniotic fluid, umbilical cord blood and placental blood after three 184 
IV doses of 1500 mg of CFX (8 hours apart)(26). The mean± SD CFX plasma levels and were 185 
32.55±5.20 mg/L 1 hour after the injection (for 4 patients) and 1.50±0.43 mg/L after 8 hours 186 
(for 3 patients). This study did not report the body weights of the pregnant women. 187 
Holt et al.(15) compared two doses of CFX (750 vs. 1500 mg) in patients that had similar 188 
median body weights (71.5 vs. 74 kg, respectively). The authors reported that the CFX 189 
placental transfer during delivery was unaffected by the mother’s body weight, with no 190 
information reported regarding the effect of mothers’ body weight on maternal CFX 191 
concentration. Additionally, in the low dose group (750 mg of CFX), the mean sampling time 192 
was shorter than in the higher dose group (1500 mg of CFX), although this was not 193 
statistically significant: 65 minutes [95% confidence interval (CI)=48.8–96.5] vs. 37 minutes 194 
(95% CI=22.8–58.3), respectively. In a subset analysis with comparable sampling time of the 195 
low dose group (47 minutes, 95% CI=32.1–67.5), maternal blood CFX concentrations were 196 
dose dependent. The group administered the higher CFX dose (1500 mg) had significantly 197 
higher CFX concentrations in the maternal blood when compared to the subset of those 198 
administered the lower dose (750 mg) (CFX concentration 51.9 vs. 19.4, P<0.001) (15). Holt 199 
et al.(15) concluded that 31% of women administered the lower dose (750 mg) would have 200 
insufficient CFX concentrations against some strains of Escherichia coli (E. coli) and Klebsiella 201 
at 75 min post administration. 202 
In a recent study, a dose of 1500 mg CFX pre-CS was investigated in healthy, hypertensive 203 
and diabetic pregnant women(11).  Initial means of CFX plasma concentration were 204 
comparable among the three groups. The mean CFX concentration in plasma at delivery in 205 
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the diabetic group was significantly higher than those in the other groups (18.54±7.30 mg/L 206 
in diabetic group, 9.47±6.28 mg/L in control group and 11.53±8.54 mg/L in hypertensive 207 
group; P≤ 0.05). The diabetic group had shorter sampling time (t=56.14±31.12 min) 208 
compared to the control group (t=99.28±47.76 min) and hypertensive group (t=79.57±54.04 209 
min). It should be noted that the minimum CFX plasma concentration reported at time of 210 
delivery were 0.9 mg/L, 2.04 mg/L and 9.85 mg/L in the control, hypertensive and diabetic 211 
group, respectively. Lean body weight-normalised volume of distribution, a hypothetical 212 
volume expressing the extent of drug distribution in plasma and body, of CFX was 213 
significantly lower in the diabetic group than in the control and hypertensive groups 214 
(537.78±91.73ml/kg in diabetic group; 1364.58±621.98 m/Kg in control group and 215 
1120.92±515.24 ml/Kg in hypertensive group; P≤ 0.05). This difference in volume of 216 
distribution may relate to the low logP value of CFX and its poor penetration into lipophilic 217 
tissues. 218 
Cefuroxime and Caesarean Section surgical site infection  219 
Literature Retrieval, Study Selection and Data Extraction 220 
Fifty-seven records were screened for inclusion based on the titles and abstracts (Figure 1). 221 
The full text of 13 studies were reviewed to assess their eligibility. Three studies were 222 
eligible, and they were evaluated for the risk of bias and quality. Data were extracted (Table 223 
2). Included studies evaluated single dose CFX administered after umbilical cord clamping; 224 
of those, 2 studies evaluated 1500 mg dosages and 1 study evaluated a 750 mg dose. 225 
Further data interpretation was not manageable as the 2 studies had different comparators; 226 
one study compared CFX to no antibiotic and the other to ampicillin/sulbactam 227 
antibiotic(27-29). No additional studies were identified that were eligible for inclusion in the 228 
updated search conducted in May 2019 229 
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Comparison of rate of infection reported in selected studies 230 
All three studies were randomised controlled trials (27-29) Two studies had acceptable 231 
quality assessment and risk of bias evaluation, except for Kristensen et al (Appendixes: Table 232 
S4 and S5).(27). Kirstensen et al.23 compared CFX (750mg) vs. no antibiotic, Rizk et al.(28) 233 
compared CFX (1500mg) vs. no antibiotic and Ziogos et al.(29) compared CFX (1500mg) vs. 234 
ampicillin/Sulbactam (3g). Patients were monitored for infection by medical team while 235 
patients were hospitalised for delivery until discharged in all studies (27-29); in addition to a 236 
weekly clinical and laboratory monitoring for 30-days in Ziogos et al.(29) and at a 6 weeks 237 
post-op visit in Rizk et al.(28). Reported rates of infection are listed in table 2. Kristensen et 238 
al.(27) demonstrated a clear advantage of IV CFX, where 1.96% of patients had a defined 239 
infection in the treatment group compared to 19.2% in the group that did not receive 240 
antibiotics. Although this was not replicated in the Rizk et al.(28) study, as higher dose of 241 
CFX (1500mg) was given to 59 women and no antibiotic to 61 women. The rate of SSI were 242 
6.8% in CFX group compared to 4.9% in the “no antibiotic” groups.  Finally, in the Ziogos et 243 
al.(29) study the incidence of SSI was 4.7% in 85 women who received 1500mg CFX 244 
compared to 6.6% in 91 women who received ampicillin/Sulbactam.  245 
The mean± SD of body weights of the women in Rizk et al.(28) study were 87±23 in CFX 246 
group vs. 81±17 in control group; while in Kristensen et al.(27) it were, at operation, 74.9± 247 
11.7 in CFX group vs. 75.6 ± 11.5 in control group. In Ziogos et al.(29), 44.7% of CFX group 248 
and 41.8% of the ampicillin/sulbactam group had a BMI of ≥ 30 kg/m2; the authors did not 249 
report infection rate when groups are classified by antibiotic administered and BMI. In this 250 
study, the univariate analysis showed no association between the overall post-op infection 251 
or post-op SSI with BMI (regardless to the antibiotic assigned). Our robust search strategy 252 
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did not identify studies evaluating the SSI after CS in obese pregnant women who were 253 
given CFX perioperatively.  254 
Discussion 255 
Cefuroxime plasma and adipose tissue concentration in obese pregnant women  256 
There was no information regarding CFX concentrations in obese pregnant women to allow 257 
comparison to non-obese women. Therefore, we evaluated plasma CFX concentrations in 258 
the non-obese population from literature identified through our search (9.85 to 95.25 mg/L 259 
within 30-60 min of administration 1500 mg CFX) with reported median CFX plasma 260 
concertation in the same population (57.2 mg/L, 82 min after administration of 2g CFZ) (8). 261 
The lipophilicity of CFX is lower than of CFZ, logP values are -0.167 and 0.3, respectively (11-262 
14). This fact, suggests that CFX is less able to penetrate adipose tissue compared to CFZ; 263 
therefore, the concentrations of CFX theoretically suspected to be lower than the reported 264 
median CFZ adipose tissue concentrations. The median adipose concentration values for CFZ 265 
in an obese population at skin incision ranged from 4.70 to 10.7 µg/g following a 2g dose of 266 
CFZ and from 6.35 to 22.4 µg/g following a 3g dose of CFZ (4, 8-10).  267 
One study reported plasma and adipose tissue concentration of CFX in six morbidly obese 268 
non-pregnant patients(30). The mean± SD maximum concentration (Cmax) of CFX in plasma 269 
was 66.8±18.9mg/L at 0.60±0.22 hour post dose, while CFX Cmax in adipose tissue was 270 
39.2±26.4 µg/g at 1.00±0.28 hour post dose (30). Although these results show reasonable 271 
penetration of CFX into adipose tissue, the authors reported insufficient MIC against E. Coli 272 
at times of prolonged surgeries (30). However, due to the unique physiological changes 273 
associated with pregnancy, specifically, with plasma volume expansion, it is inaccurate 274 
practice to extrapolate these results to the pregnant cohort of women undergoing CS (31).  275 
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Rate of post caesarean section infection  276 
The lowest rate of infection in the CFX group was reported by Kristensen et al.(27) which is 277 
interesting because patients received lower doses of CFX (750 mg) at non-elective CS. The 278 
relatively short period of follow-up (till discharge) could explain the low rate of infection(7). 279 
That this study was undertaken in 1990 could be a reflection both of the bacterial sensitivity 280 
to antibiotics and the population at the time. As previously indicated, maternal BMI has 281 
increased with time, as has antimicrobial resistance in recent times (32). 282 
The highest rate of infection in the CFX groups was found in the study by Rizk et al.(28). 283 
Mean± SD weight reported in this study was 87±23 kg for CFX group; this study had the 284 
fewest number of patients (n=59) for CFX group compared to same group in other studies. 285 
However, in this study only patients requiring elective CS were included, in contrast to the 286 
other studies (non-elective in Kristensen et al.(27) and both elective and non-elective in 287 
Ziogos et al.(29)). 288 
A recent systematic review highlighted the need for evaluating infection control bundle, 289 
infection control practice and intrinsic risk factors to assess their impact on post CS SSI (33). 290 
These would not have been in existence at the time the studies on perioperative CFX and 291 
infection were undertaken, and thus, none of the studies reported on the delivery of 292 
infection prevention bundles of care. We are therefore unable to comment if bundles of 293 
care impacted on the SSI rate.  294 
To the best of our knowledge there were no studies specifically investigating the rate of 295 
infection when CFX was administrated 30-60 min before skin incision; in this review, all 296 
included studies administrated CFX after cord clamping. This is not the current practice, 297 
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since it will not allow enough time for the drug to reach the adipose tissue and provide 298 
sufficient coverage at the time of surgery (4). 299 
A published protocol of a Danish randomised control study evaluating the rate of infection 300 
post CS was found (34); the study aimed to compare a single dose of 1500 mg CFX 301 
administered 15-60 minutes before skin incision to the same dose after cord clamping. 302 
However, the study status was withdrawn in 2013, with no patients enrolled. The exact 303 
reasons for withdrawal of the study are unknown (34). 304 
Strengths of the Study  305 
This research is the first systematic view that addressed CFX concentrations and rate of SSI 306 
in pregnant women requiring CS. The novelty of this search will enable further research in 307 
this field to determine appropriate dosing strategies for CFX. 308 
Study limitations  309 
Our search strategy could not identify one related study in CFX-INF; nevertheless, the study 310 
was not eligible(35). In CFX-PK, a total of 108 pregnant women were included in the CFX 311 
group, of whom 5 delivered spontaneously. It was considered that the type of anaesthesia 312 
and fluid administered in CS could affect the PK of drugs, specifically volume of distribution. 313 
Nevertheless, the effect of these convergences could be minor. 314 
Conclusions 315 
To the best of our knowledge, there is no study evaluating the effectiveness of CFX (in terms 316 
of CFX concentration or rate of infection post-CS) as a single IV dose peri-CS in obese 317 
pregnant women. Additionally, there were no studies assessing CFX concentrations in 318 
adipose tissue of non-obese pregnant women requiring CS. Evidence regarding the use of 319 
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CFX in non-obese pregnant women requiring CS is very sparse. There were no studies 320 
evaluating the rate of infection of single dose CFX administered as the current guidelines 321 
(30-60 min before skin incision). Owing to the importance of antibiotic resistance, future 322 
research should prioritise evaluating CFX concentration in adipose tissue for both non-obese 323 
and obese pregnant women to ensure therapeutic effectiveness from a pharmacological 324 
and clinical perspective.  325 
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